BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the 'Company'), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has entered into a definitive agreement to acquire Motion Solutions, a leading provider of highly engineered integrated solutions, for cash consideration of $189 million, subject to customary purchase price adjustments and closing conditions, including applicable regulatory approvals..

马萨诸塞州贝德福德（BUSINESS WIRE）-Novanta Inc.（纳斯达克股票代码：NOVT）（“Novanta”或“公司”）是医疗和先进技术设备制造商的受信任技术合作伙伴，今天宣布它已达成明确协议，收购Motion Solutions，这是一家高度工程化综合解决方案的领先供应商，现金考虑为1.89亿美元，根据习惯购买价格调整和关闭条件，包括适用的监管批准。。

Motion Solutions is a trusted engineering partner to market-leading original equipment manufacturers (“OEMs”) in medical, life sciences, and advanced industrial applications. Motion Solutions designs and manufactures high-precision, customized subsystems and components, specializing in proprietary precision motion and advanced motion control solutions.

Motion Solutions是一家值得信赖的工程合作伙伴，致力于销售医疗，生命科学和先进工业应用领域的领先原始设备制造商（“OEM”）。Motion Solutions设计和制造高精度，定制的子系统和组件，专门从事专有的精确运动和先进的运动控制解决方案。

The business has over 110 employees and is headquartered in Irvine, California..

该公司拥有110多名员工，总部设在加利福尼亚州欧文市。。

'Motion Solutions is an exciting business with intelligent subsystem competencies within attractive medical and precision medicine markets,” said Matthijs Glastra, Chair and Chief Executive Officer of Novanta. “The business adds complementary motion subsystem solutions to Novanta’s product portfolio, giving us greater exposure to leading OEM customers in markets such as spatial biology, genomics, proteomics, medical robotics, and lab automation.

“Motion Solutions是一家激动人心的业务，在有吸引力的医疗和精准医药市场拥有智能子系统能力，”诺华公司主席兼首席执行官Matthijs Glastra说。“该业务为Novanta的产品组合增加了互补的运动子系统解决方案，使我们更容易接触到空间生物学，基因组学，蛋白质组学，医疗机器人和实验室自动化等市场领先的OEM客户。

In addition, the transaction gives us opportunity to design unique solutions for our mutual OEM customer base combining Novanta’s and Motion Solutions’ capabilities.”.

此外，该交易使我们有机会为结合Novanta和Motion solutions功能的相互OEM客户群设计独特的解决方案。

Motion Solution is expected to generate approximately $85 million in revenue in 2023. The transaction will be financed using available cash and borrowings under the Company’s revolving credit facility.

运动解决方案预计将在2023年产生约8500万美元的收入。该交易将使用本公司旋转信用机构下的可用现金和贷款进行融资。

Conference Call Information

电话会议信息

The Company will host a conference call on Tuesday, November 14, 2023 at 5:00 p.m. ET to discuss the transaction. Matthijs Glastra, Chair and Chief Executive Officer, and Robert Buckley, Chief Financial Officer, will host the conference call. To access the call, please dial (888) 346-3959 prior to the scheduled conference call time.

本公司将于2023年11月14日星期二下午5:00召开电话会议，讨论该交易。主席兼首席执行官Matthijs Glastra和首席财务官Robert Buckley将主持电话会议。要访问电话，请在预定的电话会议时间之前拨打（888）346-3959。

Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company’s website at www.novanta.com..

或者，可以通过网站www.novanta.com上本公司网站投资者部分的活动和演示页面上的实时网络广播在线访问电话。。

A replay of the audio webcast will be available approximately three hours after the conclusion of the call in the Investor Relations section of the Company’s website at www.novanta.com. The replay will remain available until Monday, February 13, 2024.

在公司网站www.novanta.com的投资者关系部分的通话结束后约三小时，可以重播音频网络广播。重播将持续到2024年2月13日星期一。

Safe Harbor and Forward-Looking Information

安全港和前瞻性信息

Certain statements in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and are based on current expectations and assumptions that are subject to risks and uncertainties. All statements contained in this news release that do not relate to matters of historical fact should be considered forward-looking statements, and are generally identified by words such as “expect,” “intend,” “anticipate,” “estimate,” “believe,” “future,” “could,” “should,” “plan,” “aim,” and other similar expressions.

本版本中的某些陈述是1995年“私人证券诉讼改革法”含义范围内的“前瞻性陈述”，基于当前的预期和受风险和不确定性影响的假设。本新闻稿中包含的与历史事实无关的所有陈述均应视为前瞻性陈述，通常用“期望”，“意图”，“预期”，“估计”，“相信”，“未来”，“可以”，“应该”，“计划”，“目标”和其他类似的表达方式。

These forward-looking statements include, but are not limited to, statements regarding the ability of the parties to consummate the proposed transaction; the ability of the parties to satisfy the conditions precedent to consummation of the proposed transaction, including the ability to secure the applicable regulatory approvals on the terms expected, at all or in a timely manner; our ability to successfully integrate Motion Solutions, and our ability to implement our plans, forecasts and other expectations with respect to Motion Solutions’ business after the completion of the acquisition and realize expected synergies; the effect of the announcement of the proposed transaction on the ability of Motion Solutions to retain and hire key personnel and maintain relationships with its key business partners and customers, and others with whom it does business, or on its operating results and businesses generally; risks associated with the disruption of Motion Solutions management's attention from ongoing business operations due to the proposed transaction; significant costs associated with the proposed transaction; sources of funding for the Motion Solutions acquisition; benefits of the Motion Solutions acquisition; our exp.

这些前瞻性陈述包括但不限于关于各方完成拟议交易的能力的陈述；双方有能力满足完成拟议交易的先决条件，包括能够完全或及时地确保适用的监管批准符合预期条款；我们成功整合运动解决方案的能力，以及在收购完成后实现运动解决方案业务的计划，预测和其他期望的能力，并实现预期的协同效应；拟议交易公告对Motion Solutions留住和雇用关键人员的能力的影响，以及与其主要业务合作伙伴和客户，与其业务的其他人，或其一般运营结果和业务的关系；与运动解决方案中断相关的风险管理层因拟议交易而关注正在进行的业务运营；与拟议交易相关的重大成本；Motion Solutions收购的资金来源；运动解决方案获取的好处；我们的exp。

These forward-looking statements are neither promises nor guarantees, but involve risks and uncertainties that may cause actual results to differ materially from those contained in the forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, but not limited to, the following: economic and political conditions and the effects of these conditions on our customers’ businesses, capital expenditures and level of business activities; risks associated with epidemics or pandemics, and other events outside our control; our dependence upon our ability to respond to fluctuations in product demand; our ability to continually innovate, introduce new products timely, and successfully commercialize our innovations; failure to introduce new products in a timely manner; customer order timing and other similar factors may cause fluctuations in our operating results; cyberattacks, disruptions or other breaches in security of our and our third-party providers’ information technology systems; our failure to comply with data privacy regulations; changes in interest rates, credit ratings or foreign currency exchange rates; risks associated with our operations in foreign countries; our increased use of outsourcing in foreign countries; risks associated with increased outsourcing of components manufacturing; our exposure to increased tariffs, trade restrictions or taxes on our products; the continuing impact of “Brexit”; violations of our intellectual property rights and our ability to protect our intellectual property against infringement by third parties; risk of losing our competitive advantage; our failure to successfully integrate recent and future acquisitions into our business; our abili.

这些前瞻性陈述既不是承诺也不是保证，但涉及可能导致实际结果与前瞻性陈述中包含的实际结果大不相同的风险和不确定性。我们的实际结果可能与这些前瞻性声明中预期的结果有很大不同，原因很多，包括但不限于以下内容：经济和政治条件以及这些条件对客户业务，资本支出和水平的影响商业活动；与流行病或流行病有关的风险以及我们控制之外的其他事件；我们依赖我们应对产品需求波动的能力；我们不断创新，及时引进新产品，成功实现创新商业化的能力；未能及时引进新产品；客户订单时间和其他类似因素可能会导致我们的运营结果出现波动；网络攻击，破坏或其他违反我们和我们第三方提供商信息技术系统安全的行为；我们未能遵守数据隐私法规；利率，信用评级或外语汇率变动；与我们在外国运营相关的风险；我们在外国越来越多地使用外包；与组件制造外包增加有关的风险；我们面临增加关税，贸易限制或产品税的风险；“Brexit”的持续影响；违反我们的知识产权和保护我们的知识产权免受第三方侵犯的能力；失去竞争优势的风险；我们未能成功将近期和未来的收购整合到我们的业务中；我们的abili。

Other important risk factors that could affect the outcome of the events set forth in these statements and that could affect the Company’s operating results and financial condition are discussed in Item 1A of our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as updated by our Quarterly Report on Form 10-Q for the quarterly period ended September 29, 2023 and other subsequent filings with the Securities and Exchange Commission.

其他可能影响本报表所列事件结果并可能影响公司经营业绩和财务状况的重要风险因素，在截至12月31日财政年度表格10-K年度报告第1A项中讨论，2022年，根据我们截至9月29日的季度表格10-Q季度报告的更新，2023年及随后向证券交易委员会提交的其他文件。

Such statements are based on the Company’s beliefs and assumptions and on information currently available to the Company. The Company disclaims any obligation to publicly update or revise any information included in this release or any forward-looking statements as a result of developments occurring after the date of this document except as required by law..

此类陈述基于公司的信念和假设以及公司当前可用的信息。除法律要求外，本公司不承担任何公开更新或修改本版本中包含的任何信息或由于本文档发布之日后发生的任何前瞻性声明的义务。。

About Novanta

关于Novanta

Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive advantage. We combine deep proprietary technology expertise and competencies in precision medicine and manufacturing, medical solutions, and robotics and automation with a proven ability to solve complex technical challenges.

诺华是核心技术解决方案的全球领先供应商，为医疗和先进的工业原始设备制造商提供竞争优势。我们将精密医学和制造，医疗解决方案，机器人和自动化方面的深入专有技术专业知识和能力与经过验证的解决复杂技术挑战的能力相结合。

This enables Novanta to engineer core components and sub-systems that deliver extreme precision and performance, tailored to our customers' demanding applications. The driving force behind our growth is the team of innovative professionals who share a commitment to innovation and customer success. Novanta’s common shares are quoted on Nasdaq under the ticker symbol “NOVT.”.

这使Novanta能够设计出能够提供极高精度和性能的核心组件和子系统，根据客户的苛刻应用量身定制。我们成长背后的推动力是创新专业人士团队，他们致力于创新和客户成功。Novanta的普通股在纳斯达克以勾号“NOVT”报价。

More information about Novanta is available on the Company’s website at www.novanta.com. For additional information, please contact Novanta Investor Relations at (781) 266-5137 or InvestorRelations@novanta.com.

有关Novanta的更多信息，请访问公司网站www.Novanta.com。有关更多信息，请致电（781）266-5137或联系Novanta Investor RelationsInvestorRelations@novanta.com.